PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34118937-0	2021	Evaluation of the effect of MTNR1B rs10830963 gene variant on the therapeutic efficacy of nateglinide in treating type 2 diabetes among Chinese Han patients.	Nateglinide	90-101	melatonin receptor 1B	Homo sapiens	28-34	
34118937-1	2021	Genetic polymorphisms in the MTNR1B gene is associated with type 2 diabetes mellitus (T2DM); however, there is no evidence about its impact on the therapeutic efficacy of nateglinide.	Nateglinide	171-182	melatonin receptor 1B	Homo sapiens	29-35	
34118937-2	2021	This prospective case-control study was designed to investigate the effect of MTNR1B rs10830963 gene variant on the therapeutic efficacy of nateglinide in treating T2DM.	Nateglinide	140-151	melatonin receptor 1B	Homo sapiens	78-84	
34118937-8	2021	MTNR1B rs10830963 polymorphism was associated with the therapeutic efficacy of nateglinide in T2DM patients.	Nateglinide	79-90	melatonin receptor 1B	Homo sapiens	0-6